Evidence map›Paper›PMID 32666362›Full record

SynthesisTechniques in coloproctology2020

Neoadjuvant chemotherapy in locally advanced colon cancer: a systematic review.

J Arredondo, E Pastor, V Simó, M Beltrán, C Castañón, M C Magdaleno, I Matanza, M Notarnicola, B Ielpo

Open access · bronzeAbstract readSystematic Review
PubMed Publisher
In one paragraph

Synthesis in Techniques in coloproctology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed, 2 pooled it
2.9field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 2 syntheses or guidelines pooled it, 57 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. The ELECLA trial: A multicentre randomised control trial on outcomes of neoadjuvant treatment on locally advanced colon cancer.Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland · 2024
    Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

J ArredondoUnit of Coloproctology, Service of General Surgery, University Hospital of Leon, 24071, C/Altos de Nava s/n León, Spain. jarredondo@outlook.es.ORCID 0000-0001-8077-6092
E PastorUnit of Coloproctology, Service of General Surgery, University Hospital of Leon, 24071, C/Altos de Nava s/n León, Spain.
V SimóUnit of Coloproctology, Service of General Surgery, University Hospital of Leon, 24071, C/Altos de Nava s/n León, Spain.
M BeltránUnit of Coloproctology, Service of General Surgery, University Hospital of Leon, 24071, C/Altos de Nava s/n León, Spain.
C CastañónService of Oncology, University Hospital of León, León, Spain.
M C MagdalenoService of Radiology, University Hospital of León, León, Spain.
I MatanzaService of Pathology, University Hospital of León, León, Spain.
M NotarnicolaService of General Surgery, Università Degli Studi Di Bari, Bari, Italy.
B IelpoUnit of Coloproctology, Service of General Surgery, University Hospital of Leon, 24071, C/Altos de Nava s/n León, Spain.
Hospital de León · ESUniversity of Bari Aldo Moro · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPreoperative or neoadjuvant chemotherapy (NAC) has emerged as a novel alternative to treat locally advanced colon cancer (LACC), as in other gastrointestinal malignancies. However, evidence of its efficacy and safety has not yet been gathered in the literature. The aim of the present study was to perform an extensive review of the scientific evidence for NAC in patients with LACC.

methodsPubMed, EMBASE, MEDLINE and Cochrane Library were searched for a systematic review of the literature from 2010 to 2019. Six eligible studies were included, with a total of 27,937 patients, 1232 of them (4.4%) treated with NAC. There were only one randomized controlled trial, three phase II non-randomized single arm studies and two retrospective studies.

resultsThe baseline computed tomography scan showed that most of patients had a T3 tumor. The completion rate of the planned neoadjuvant treatment ranged from 52.5 to 93.8%. Between 97.2 and 100% of patients had the scheduled surgery. The median tumor volume reduction after NAC ranged from 62.5 to 63.7%. The anastomotic leak rate in the NAC group ranged from 0 to 7%, with no cases of postoperative mortality. There was major pathological tumor regression in 4-34.7% of cases. Between 84 and 100% of NAC patients had R0-surgery. Survival after NAC seems to be encouraging although significant improvement has only been proven in T4b tumours.

conclusionsAccording to our systematic review, the NAC may be a safe and effective emerging therapeutic alternative for treating LACC. This approach, which is still being tested, increases the reliance on accurate radiological staging.

Indexed as

Colonic NeoplasmsNeoadjuvant TherapyAntineoplastic Combined Chemotherapy ProtocolsChemotherapy, AdjuvantHumansNeoplasm StagingRetrospective StudiesColonic neoplasmsLocally advanced colon cancerMorbidityNeoadjuvant therapyTreatment outcome

Identifiers

PMID32666362
OpenAlexW3043347616

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.